2014
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeType C lesionsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsC lesionsLesion complexityBivalirudin monotherapyComposite ischemiaCoronary syndromeCoronary interventionIschemic eventsMyocardial infarctionCardiology/American Heart Association classificationAdverse short-term prognosisAmerican Heart Association classificationAdverse ischemic eventsComposite ischemic eventsContemporary interventional therapyMajor bleeding complicationsMajor hemorrhagic complicationsShort-term prognosisAcute CatheterizationAntithrombotic regimensMajor bleeding
2012
Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens
Acharji S, Baber U, Mehran R, Fahy M, Kirtane AJ, Lansky AJ, Stone GW. Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens. Circulation Cardiovascular Interventions 2012, 5: 157-165. PMID: 22354934, DOI: 10.1161/circinterventions.111.963876.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overBiomarkersFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHumansKidney Failure, ChronicMaleMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsReference StandardsSurvival AnalysisTroponin TConceptsGlycoprotein IIb/IIIa inhibitorsAcute coronary syndromeBaseline troponin elevationChronic kidney diseaseMajor adverse cardiac eventsTroponin elevationMyocardial infarctionBivalirudin monotherapyMajor bleedingCKD patientsCoronary syndromeBaseline troponinKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsLong-term clinical outcomesBaseline cardiac troponinBaseline troponin levelsDifferent antithrombotic regimensAdverse cardiac eventsACS patientsACUITY trialAntithrombotic regimensComposite deathRandomization arm
2011
Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rateImpact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial)
Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108: 1387-1394. PMID: 21864816, DOI: 10.1016/j.amjcard.2011.06.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug UtilizationFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPyridinesRecombinant ProteinsSmokingStentsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary percutaneous coronary interventionProbable stent thrombosisPercutaneous coronary interventionUnfractionated heparinStent thrombosisMajor bleedingMyocardial infarctionBivalirudin monotherapyCoronary interventionSmoking statusPaclitaxel-eluting stent implantationIIb/IIIa inhibitorsAlternative antithrombotic regimensHORIZONS-AMI trialOutcomes of patientsImpact of smokingPaclitaxel-eluting stentsBare metal stentsLate stent thrombosisAntithrombotic regimensIschemic eventsIndependent predictorsFrequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictorsIncidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial
Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal 2011, 161: 298-306.e1. PMID: 21315212, DOI: 10.1016/j.ahj.2010.10.035.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsGP IIb/IIIa inhibitorsAcute coronary syndromeBivalirudin monotherapyMajor bleedingCoronary syndromePlatelet countClinical consequencesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsPredictors of mortalityAcquired thrombocytopeniaACUITY trialAcute CatheterizationAntiplatelet medicationsAntithrombotic therapyIschemic complicationsAnticoagulant regimenIndependent predictorsStrategy trialThrombocytopeniaPatientsMultivariate analysisMonotherapyLess decline
2009
Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials
DOLL JA, NIKOLSKY E, STONE GW, MEHRAN R, LINCOFF AM, CAIXETA A, MCLAURIN B, CRISTEA E, FAHY M, KESANAKURTHY V, LANSKY AJ. Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials. Journal Of Interventional Cardiology 2009, 22: 453-459. PMID: 19702677, DOI: 10.1111/j.1540-8183.2009.00494.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChemotherapy, AdjuvantCoronary VesselsDrug Therapy, CombinationFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsSurvival RateTreatment OutcomeWounds, PenetratingConceptsPercutaneous coronary interventionGP IIb/IIIa inhibitorsIIb/IIIa inhibitorsAdjunctive antithrombotic therapyUnfractionated heparinMyocardial infarctionAntithrombotic therapyCoronary interventionPCI trialProvisional glycoprotein (GP) IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionBaseline creatinine clearanceHORIZONS-AMI trialGP IIb/IIIaOutcomes of patientsOnly independent predictorCoronary artery perforationManagement of patientsTreatment of patientsIIb/IIIaLower ratesSimilar ratesBivalirudin monotherapyHORIZONS-AMIImpact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy
Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, Stone GW. Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy. JACC Cardiovascular Interventions 2009, 2: 748-757. PMID: 19695543, DOI: 10.1016/j.jcin.2009.05.018.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBiomarkersChronic DiseaseCoronary Artery BypassCreatinineDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansKidney DiseasesLogistic ModelsMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaOdds RatioPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsRisk AssessmentTime FactorsTreatment OutcomeTriageConceptsGlycoprotein IIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeBivalirudin monotherapyComposite ischemiaMajor bleedingCoronary syndromeClinical outcomesKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsClinical adverse outcomesCreatinine clearance dataOutcomes of patientsNormal renal functionAdverse event ratesAntithrombotic treatment strategiesSignificant differencesACUITY trialIschemic outcomesRenal functionAdverse outcomesInvasive strategyLate outcomesTreatment strategiesImpact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial)
Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial). The American Journal Of Cardiology 2009, 103: 1196-1203. PMID: 19406258, DOI: 10.1016/j.amjcard.2009.01.030.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAge FactorsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsCause of DeathDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyEnoxaparinFemaleFollow-Up StudiesHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsReference ValuesRisk AssessmentSeverity of Illness IndexSex FactorsSurvival AnalysisTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsElevation acute coronary syndromePercutaneous coronary interventionAcute coronary syndromeComposite ischemiaNet clinical outcomeMajor bleedingCoronary syndromeClinical outcomesNet clinical adverse eventsIIb/IIIa inhibitorsLate clinical outcomesCoronary artery bypassClinical adverse eventsImpact of genderACUITY trialBivalirudin monotherapyAntithrombotic therapyArtery bypassNon–STAdverse eventsAntithrombotic strategiesCoronary interventionIschemiaBivalirudin
2008
Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. Journal Of The American College Of Cardiology 2008, 52: 807-814. PMID: 18755342, DOI: 10.1016/j.jacc.2008.05.036.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsDrug Therapy, CombinationEnoxaparinFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk FactorsTime FactorsConceptsIIb/IIIa inhibitorsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsHigh-risk ACS patientsImpact of bivalirudinUnfractionated heparinACUITY trialComposite ischemiaACS patientsCoronary interventionAcute coronary syndrome patientsEfficacy of bivalirudinLess major bleedingSimilar ischemic outcomesAcute coronary syndromeCoronary syndrome patientsBivalirudin monotherapyIschemic outcomesMajor bleedingCoronary syndromeSyndrome patientsBivalirudinPatientsEnoxaparin